Chad Patterson Sells 4,444 Shares of iRhythm Technologies (NASDAQ:IRTC) Stock

iRhythm Technologies (NASDAQ:IRTC) insider Chad Patterson sold 4,444 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $128.44, for a total transaction of $570,787.36. Following the completion of the transaction, the insider directly owned 58,164 shares in the company, valued at approximately $7,470,584.16. The trade was a 7.10% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Chad Patterson also recently made the following trade(s):

• On Wednesday, February 25th, Chad Patterson sold 8,967 shares of iRhythm Technologies stock. The shares were sold at an average price of $135.42, for a total transaction of $1,214,311.14.

iRhythm Technologies Trading Up 1.7%

Shares of iRhythm Technologies stock opened at $127.95 on Thursday. The company’s fifty day simple moving average is $158.44 and its 200-day simple moving average is $169.85. The stock has a market capitalization of $4.14 billion, a PE ratio of -91.39 and a beta of 1.09. iRhythm Technologies has a 1-year low of $92.52 and a 1-year high of $212.00. The company has a debt-to-equity ratio of 4.25, a current ratio of 4.63 and a quick ratio of 4.48.

iRhythm Technologies (NASDAQ:IRTC) last posted its quarterly earnings data on Thursday, February 19th. The company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.02 by $0.27. The firm had revenue of $208.89 million during the quarter, compared to analyst estimates of $202.61 million. iRhythm Technologies had a negative return on equity of 28.15% and a negative net margin of 5.96%.iRhythm Technologies’s revenue was up 27.1% on a year-over-year basis. During the same period in the prior year, the business posted ($0.04) EPS. As a group, equities analysts anticipate that iRhythm Technologies will post -1.98 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on IRTC. Robert W. Baird decreased their target price on shares of iRhythm Technologies from $220.00 to $200.00 and set an “outperform” rating on the stock in a research note on Friday, February 20th. Wall Street Zen raised shares of iRhythm Technologies from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Wells Fargo & Company lowered their target price on shares of iRhythm Technologies from $225.00 to $200.00 and set an “overweight” rating on the stock in a research note on Friday, February 20th. Freedom Capital raised shares of iRhythm Technologies to a “strong-buy” rating in a report on Thursday, January 15th. Finally, Canaccord Genuity Group decreased their price target on iRhythm Technologies from $212.00 to $198.00 and set a “buy” rating on the stock in a report on Friday, February 20th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, iRhythm Technologies presently has a consensus rating of “Moderate Buy” and an average target price of $211.62.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Tudor Investment Corp ET AL bought a new position in iRhythm Technologies during the third quarter valued at approximately $3,439,800,000. Vanguard Group Inc. grew its holdings in iRhythm Technologies by 2.2% during the 4th quarter. Vanguard Group Inc. now owns 3,310,519 shares of the company’s stock valued at $587,418,000 after purchasing an additional 70,420 shares during the last quarter. RTW Investments LP purchased a new stake in iRhythm Technologies in the 4th quarter worth about $209,732,000. Geode Capital Management LLC lifted its stake in iRhythm Technologies by 8.6% in the fourth quarter. Geode Capital Management LLC now owns 858,405 shares of the company’s stock worth $152,337,000 after purchasing an additional 68,301 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of iRhythm Technologies by 45.6% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 829,862 shares of the company’s stock valued at $147,251,000 after buying an additional 259,800 shares during the period.

iRhythm Technologies News Summary

Here are the key news stories impacting iRhythm Technologies this week:

• Positive Sentiment: Management raised FY‑2026 revenue guidance to $870.0M–$880.0M versus consensus near $817M, signaling stronger demand and faster revenue growth than expected; the company also reported a solid February quarter beat (revenue +27% YoY and EPS above estimates), supporting the outlook.
• Neutral Sentiment: Analysts are recalibrating assumptions: several firms trimmed price targets while mostly keeping Buy/Overweight ratings — that creates mixed analyst signals as models are adjusted around the new guidance and profitability timing. Analyst coverage note
• Negative Sentiment: Clustered insider selling on March 2: multiple senior executives (CAO and several EVPs) sold shares — collectively roughly 17.8k shares for ≈$2.3M at ~ $128.44 per share — a mid‑single‑digit reduction in each holder’s stake. While insiders still retain material positions, the concentrated timing of the sales is likely weighing on near‑term sentiment. Insider trades alert

About iRhythm Technologies

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.